Cargando…

Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine

This single-center study included 68 multiple sclerosis (MS) patients who received the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from one of several approved vaccine preparations in Spain. Blood samples were collected one to three months after the second dose of the va...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodero-Romero, Alexander, Sainz de la Maza, Susana, Fernández-Velasco, José Ignacio, Monreal, Enric, Walo-Delgado, Paulette Esperanza, Chico-García, Juan Luis, Villarrubia, Noelia, Rodríguez-Jorge, Fernando, Rodríguez-Ramos, Rafael, Masjuan, Jaime, Costa-Frossard, Lucienne, Villar, Luisa María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535818/
https://www.ncbi.nlm.nih.gov/pubmed/37766078
http://dx.doi.org/10.3390/vaccines11091399
_version_ 1785112719428419584
author Rodero-Romero, Alexander
Sainz de la Maza, Susana
Fernández-Velasco, José Ignacio
Monreal, Enric
Walo-Delgado, Paulette Esperanza
Chico-García, Juan Luis
Villarrubia, Noelia
Rodríguez-Jorge, Fernando
Rodríguez-Ramos, Rafael
Masjuan, Jaime
Costa-Frossard, Lucienne
Villar, Luisa María
author_facet Rodero-Romero, Alexander
Sainz de la Maza, Susana
Fernández-Velasco, José Ignacio
Monreal, Enric
Walo-Delgado, Paulette Esperanza
Chico-García, Juan Luis
Villarrubia, Noelia
Rodríguez-Jorge, Fernando
Rodríguez-Ramos, Rafael
Masjuan, Jaime
Costa-Frossard, Lucienne
Villar, Luisa María
author_sort Rodero-Romero, Alexander
collection PubMed
description This single-center study included 68 multiple sclerosis (MS) patients who received the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from one of several approved vaccine preparations in Spain. Blood samples were collected one to three months after the second dose of the vaccine had been administered. Cellular immune responses to the vaccine were assessed using QuantiFERON analysis, and peripheral blood mononuclear cell subsets were assayed using flow cytometry. Response associated with higher percentages of total lymphocytes, naïve CD4+ T-cells (p = 0.028), CD8+ T-cells (p = 0.013), and, mostly, naïve CD8+ T-cells (p = 0.0003). These results were confirmed by analyzing absolute numbers (p = 0.019; p = 0.002, and p = 0.0003, respectively). Naïve CD8 T-cell numbers higher than 17 cells/μL were closely associated with an optimal cellular response to SARS-CoV-2 vaccination (odds ratio: 24.0, confidence interval: 4.8–460.3; p = 0.0001). This finding clearly shows that independent of the treatment received, higher numbers of naïve CD8+ T-cells yield a strong cellular response to SARS-CoV-2 vaccines in MS patients. If this finding is validated with other viruses/vaccines, it could provide a good tool for identifying MS patients undergoing treatment who will develop strong cellular responses to anti-virus vaccines.
format Online
Article
Text
id pubmed-10535818
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105358182023-09-29 Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine Rodero-Romero, Alexander Sainz de la Maza, Susana Fernández-Velasco, José Ignacio Monreal, Enric Walo-Delgado, Paulette Esperanza Chico-García, Juan Luis Villarrubia, Noelia Rodríguez-Jorge, Fernando Rodríguez-Ramos, Rafael Masjuan, Jaime Costa-Frossard, Lucienne Villar, Luisa María Vaccines (Basel) Article This single-center study included 68 multiple sclerosis (MS) patients who received the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from one of several approved vaccine preparations in Spain. Blood samples were collected one to three months after the second dose of the vaccine had been administered. Cellular immune responses to the vaccine were assessed using QuantiFERON analysis, and peripheral blood mononuclear cell subsets were assayed using flow cytometry. Response associated with higher percentages of total lymphocytes, naïve CD4+ T-cells (p = 0.028), CD8+ T-cells (p = 0.013), and, mostly, naïve CD8+ T-cells (p = 0.0003). These results were confirmed by analyzing absolute numbers (p = 0.019; p = 0.002, and p = 0.0003, respectively). Naïve CD8 T-cell numbers higher than 17 cells/μL were closely associated with an optimal cellular response to SARS-CoV-2 vaccination (odds ratio: 24.0, confidence interval: 4.8–460.3; p = 0.0001). This finding clearly shows that independent of the treatment received, higher numbers of naïve CD8+ T-cells yield a strong cellular response to SARS-CoV-2 vaccines in MS patients. If this finding is validated with other viruses/vaccines, it could provide a good tool for identifying MS patients undergoing treatment who will develop strong cellular responses to anti-virus vaccines. MDPI 2023-08-22 /pmc/articles/PMC10535818/ /pubmed/37766078 http://dx.doi.org/10.3390/vaccines11091399 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rodero-Romero, Alexander
Sainz de la Maza, Susana
Fernández-Velasco, José Ignacio
Monreal, Enric
Walo-Delgado, Paulette Esperanza
Chico-García, Juan Luis
Villarrubia, Noelia
Rodríguez-Jorge, Fernando
Rodríguez-Ramos, Rafael
Masjuan, Jaime
Costa-Frossard, Lucienne
Villar, Luisa María
Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine
title Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine
title_full Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine
title_fullStr Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine
title_full_unstemmed Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine
title_short Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine
title_sort blood cd8+ naïve t-cells identify ms patients with high probability of optimal cellular response to sars-cov-2 vaccine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535818/
https://www.ncbi.nlm.nih.gov/pubmed/37766078
http://dx.doi.org/10.3390/vaccines11091399
work_keys_str_mv AT roderoromeroalexander bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine
AT sainzdelamazasusana bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine
AT fernandezvelascojoseignacio bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine
AT monrealenric bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine
AT walodelgadopauletteesperanza bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine
AT chicogarciajuanluis bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine
AT villarrubianoelia bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine
AT rodriguezjorgefernando bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine
AT rodriguezramosrafael bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine
AT masjuanjaime bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine
AT costafrossardlucienne bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine
AT villarluisamaria bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine